Completed PHASE4 INTERVENTIONAL 1-arm NCT02450487

Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery

Influence of Genotype of Cytochrome P450 (CYP2C9) on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery

Sponsor: Fundação de Amparo à Pesquisa do Estado de São Paulo

Conditions Cytochrome P450 CYP2C9 Enzyme Deficiency Impacted Third Molar Tooth Other Surgical Procedures Pain

Interventions Piroxicam

Updated 7 times since 2017 Last updated: Sep 11, 2020 Started: Oct 31, 2012 Primary completion: Oct 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Cytochrome P450 CYP2C9 Enzyme Deficiency and Impacted Third Molar Tooth and is currently completed. Fundação de Amparo à Pesquisa do Estado de São Paulo leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Oct 2020 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Oct 2020 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundação de Amparo à Pesquisa do Estado de São Paulo
University of Sao Paulo

Data source: University of Sao Paulo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.